MAXCYTE INC COM STK USD0.01 (DI) news, videos and press releases - Page 3
For more news please use our advanced search feature.
MAXCYTE INC COM STK USD0.01 (DI) - More news...
MAXCYTE INC COM STK USD0.01 (DI) - More news...
- MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue
- MaxCyte Reports Fourth Quarter and Full Year Financial Results
- MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
- MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
- MaxCyte to Participate in Upcoming Investor Conferences
- MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
- MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results
- MaxCyte to Participate in Upcoming Investor Conferences
- MaxCyte Reports Third Quarter Financial Results
- MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board
- Result of AGM
- MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
- MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021
- MaxCyte Set to Join Russell 2000® Index
- MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections
- MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
- MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
- MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
- MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market
- MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
-
MaxCyte - Edison Open House Interview
- MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
- MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
